Providing Access to Cord Blood Units for Transplants
- Cord blood banks have been set up to collect and store umbilical cord blood for transplants. These transplants are used to treat different types of cancer. In October 2011, the Food and Drug Administration (FDA) began considering cord blood as a biological drug. Most of the cord blood units currently available in cord blood banks in the United States and other countries were collected before the FDA set these new standards. The units meet standards set by the National Marrow Donor Program (NMDP), but they were not collected, tested, or stored exactly according to FDA standards. As a result, the new guidelines state that they may only be used for transplant if the transplant is done as part of a study. Researchers have set up a study to provide these cord blood units to recipients and to study the effects of their use.
- To provide access to cord blood units for recipients whose best choice for a unit meets NMDP but not FDA standards.
- To study the effects of these cord blood transplants.
- Individuals who need to have a cord blood transplant to treat certain types of cancer.
- Participants will be screened with a physical exam, medical history. They will also have blood tests and imaging studies.
- Participants will have the cord blood transplant and allow their medical data to be collected by the study researchers.
Chronic Myelogous Leukemia/Other Leukemia
Drug: Access to unlicensed cord blood units
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
|Official Title:||A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications|
- The primary aim of this study is to examine the incidence of neutrophil recovery of greater than or equal to 500/mm3 after cord blood transplantation in a multi-institution setting using CBUs that are not Food and Drug Administration (FDA) licen...
- Assess incidence of graft rejection.
- Assess incidence of transmission of infection.
- Assess incidence of serious infusion reaction.
- Determine 1 year survival after cord blood transplantation.
- Assess cumulative incidence of aGVHD vs cGVHD.
|Study Start Date:||October 27, 2011|
|Study Completion Date:||November 26, 2012|
|Primary Completion Date:||November 26, 2012 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01479582
|Principal Investigator:||Ronald E Gress, M.D.||National Cancer Institute (NCI)|